Advanced View of Predictions and Scores
| # | Report Date | Ticker | Mkt Cap (mln) |
AI Headline | Window Start | Window End | Time (days) | Close @Rpt Time |
Proj High |
Proj ROI |
Entry | Max | End | Max ROI |
End ROI |
Actual ROI |
Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 226 | 2026-06-09 | CRBP | 162 | Corbus Faces Its Next Real Repricing On… | 2026-07-20 | 2026-08-28 | 39 | 7.65 | 13.50 | 76% | |||||||
| 225 | 2026-06-09 | MNPR | 587 | Mid 2026 NDA Filing Could Reignite Mono… | 2026-06-22 | 2026-07-17 | 25 | 60.34 | 84.00 | 39% | 68.66 | 94.83 | 86.40 | 38.11% | 25.83% | 22.34% | Breakout |
| 224 | 2026-06-07 | ATYR | 52 | June IND Reset Could Spark ATyr’s Post … | 2026-06-16 | 2026-07-03 | 17 | 0.4700 | 0.9500 | 102% | 0.4478 | 0.5948 | 0.5674 | 32.83% | 26.71% | 26.71% | Missed |
| 223 | 2026-05-31 | ZNTL | 288 | ASCO Follow Through Could Spark Zentali… | 2026-06-02 | 2026-06-10 | 8 | 4.00 | 5.60 | 40% | 3.95 | 4.06 | 3.60 | 2.74% | -8.86% | -8.86% | Missed |
| 222 | 2026-05-31 | UNCY | 190 | UNCY Faces Make Or Break FDA Catalyst W… | 2026-06-22 | 2026-07-03 | 11 | 7.38 | 14.00 | 90% | 7.87 | 8.56 | 6.89 | 8.77% | -12.45% | -12.45% | Missed |
| 221 | 2026-05-31 | MAIA | 86 | Late Stage NSCLC Progress Could Reawake… | 2026-08-10 | 2026-09-18 | 39 | 1.39 | 2.60 | 87% | |||||||
| 220 | 2026-05-30 | IMRX | 308 | ASCO Data Will Decide Whether IMRX Earn… | 2026-06-01 | 2026-06-05 | 4 | 5.77 | 8.75 | 52% | 4.50 | 5.68 | 4.27 | 26.35% | -5.01% | -5.01% | Missed |
| 219 | 2026-05-30 | ACET | 88 | Midyear Prula Cel Data Could Redefine A… | 2026-06-24 | 2026-07-17 | 23 | 9.31 | 15.50 | 66% | 8.25 | 8.43 | 8.22 | 2.18% | -0.36% | -0.36% | Missed |
| 218 | 2026-05-28 | CRDF | 85 | ASCO Data Could Decide Cardiff Oncology… | 2026-05-30 | 2026-06-06 | 7 | 1.87 | 3.60 | 93% | 1.48 | 1.79 | 1.50 | 20.93% | 1.35% | 1.35% | Missed |
| 217 | 2026-05-24 | ACHV | 618 | ACHV Faces Make Or Break FDA Catalyst W… | 2026-06-10 | 2026-06-24 | 14 | 4.69 | 9.00 | 92% | 5.75 | 6.16 | 5.30 | 7.13% | -7.83% | -7.83% | Missed |
| 216 | 2026-05-20 | AVIR | 359 | Phase 3 HCV Data Could Decide Atea’s Ne… | 2026-06-15 | 2026-07-24 | 39 | 4.25 | 8.50 | 100% | 4.35 | 4.58 | 4.45 | 5.29% | 2.3% | 2.3% | Missed |
| 215 | 2026-05-20 | LXEO | 373 | Lexeo Nears Pivotal FDA Decision That C… | 2026-06-01 | 2026-07-03 | 32 | 5.12 | 8.50 | 66% | 4.81 | 5.34 | 4.69 | 11.02% | -2.49% | -2.49% | Missed |
| 214 | 2026-05-20 | IRD | 326 | June Science Forum May Reset Opus Genet… | 2026-06-09 | 2026-06-24 | 15 | 4.36 | 6.20 | 42% | 4.08 | 4.29 | 3.71 | 5.15% | -9.07% | -9.07% | Missed |
| 213 | 2026-05-20 | BNTC | 425 | Benitec’s Next Rerating Likely Hinges O… | 2026-06-15 | 2026-07-17 | 32 | 11.04 | 18.50 | 68% | 11.33 | 14.33 | 12.59 | 26.48% | 11.12% | 11.12% | Missed |
| 212 | 2026-05-20 | AUTL | 428 | Next Autolus Rerating Likely Hinges On … | 2026-07-30 | 2026-08-18 | 19 | 1.65 | 2.60 | 58% | |||||||
| 211 | 2026-05-20 | ABEO | 320 | ZEVASKYN Launch Traction Could Force AB… | 2026-06-08 | 2026-07-03 | 25 | 5.32 | 7.40 | 39% | 5.38 | 5.88 | 5.58 | 9.29% | 3.72% | 3.72% | Missed |
| 210 | 2026-05-12 | NGNE | 506 | Mid 2026 Rett Data Could Reignite Neuro… | 2026-06-10 | 2026-07-10 | 30 | 31.54 | 45.00 | 43% | 28.01 | 32.97 | 31.37 | 17.69% | 12% | 12% | Missed |
| 209 | 2026-05-10 | NGEN | 199 | NervGen’s Next Rerating Likely Hinges O… | 2026-06-08 | 2026-06-30 | 22 | 3.82 | 6.25 | 64% | 1.82 | 2.35 | 1.87 | 28.85% | 2.47% | 2.47% | Missed |
| 208 | 2026-05-10 | LRMR | 382 | June BLA Filing Could Reset Larimar’s R… | 2026-06-08 | 2026-06-26 | 18 | 4.15 | 7.50 | 81% | 3.10 | 3.86 | 3.52 | 24.41% | 13.39% | 13.39% | Missed |
| 207 | 2026-05-10 | AUTL | 428 | Autolus Faces Its First True Commercial… | 2026-05-12 | 2026-05-19 | 7 | 1.63 | 2.40 | 47% | 1.60 | 1.95 | 1.63 | 21.87% | 1.87% | 1.87% | Missed |
| 206 | 2026-05-10 | ABEO | 320 | ZEVASKYN Launch Proof Could Ignite Abeo… | 2026-05-12 | 2026-05-16 | 4 | 5.84 | 7.40 | 27% | 5.68 | 5.93 | 5.49 | 4.37% | -3.35% | -3.35% | Missed |
| 205 | 2026-05-10 | NMRA | 304 | Phase 3 Redemption Window Nears For Bea… | 2026-05-26 | 2026-06-26 | 31 | 1.83 | 5.50 | 201% | 1.84 | 1.96 | 1.59 | 6.52% | -13.59% | -13.59% | Missed |
| 204 | 2026-05-02 | TNYA | 156 | ASGCT TN 401 Data Could Decide Tenaya’s… | 2026-05-08 | 2026-05-20 | 12 | 0.7206 | 1.35 | 87% | 1.00 | 1.15 | 0.8081 | 15% | -19.19% | -19.19% | Missed |
| 203 | 2026-05-02 | PYPD | 91 | PolyPid Nears NDA Completion With Regul… | 2026-06-08 | 2026-07-03 | 25 | 4.44 | 6.75 | 52% | 4.62 | 5.20 | 4.66 | 12.55% | 0.87% | 0.87% | Missed |
| 202 | 2026-05-02 | PRQR | 161 | AX 0810 Human Proof Of Mechanism Could … | 2026-06-08 | 2026-06-30 | 22 | 1.55 | 3.20 | 107% | 1.53 | 1.98 | 1.55 | 29.41% | 0.98% | 0.98% | Missed |
| 201 | 2026-05-02 | OSTX | 84 | OSTX Faces Its Defining FDA Pathway Tes… | 2026-05-18 | 2026-05-29 | 11 | 1.64 | 3.40 | 107% | 1.73 | 2.19 | 2.14 | 26.59% | 23.7% | 23.7% | Missed |
| 200 | 2026-05-02 | OBIO | 254 | HRS AVIM Data Could Spark OBIO’s Next R… | 2026-05-04 | 2026-05-12 | 8 | 3.97 | 5.80 | 46% | 4.02 | 4.24 | 4.06 | 5.47% | 1% | 1% | Missed |
| 199 | 2026-05-02 | INO | 91 | Depressed Inovio May Rebound On FDA Rev… | 2026-05-08 | 2026-05-22 | 14 | 1.12 | 1.85 | 65% | 1.46 | 1.79 | 1.35 | 22.6% | -7.53% | -7.53% | Missed |
| 198 | 2026-05-02 | ADAG | 278 | Next ADAG Move Likely Hinges On Executi… | 2026-06-15 | 2026-08-15 | 61 | 3.81 | 5.40 | 42% | 3.64 | 4.45 | 4.20 | 22.25% | 15.38% | 15.38% | Missed |
| 197 | 2026-05-02 | ACXP | 7 | Microcap ACXP Hinges On Proof Ibezapols… | 2026-05-06 | 2026-05-22 | 16 | 2.20 | 4.50 | 105% | 2.09 | 2.22 | 1.97 | 6.22% | -5.74% | -5.74% | Missed |
| 196 | 2026-05-02 | GANX | 75 | GANX Faces A Crucial May Test For Parki… | 2026-05-12 | 2026-05-29 | 17 | 1.87 | 3.40 | 82% | 1.80 | 2.05 | 1.95 | 13.89% | 8.33% | 8.33% | Missed |
| 195 | 2026-05-02 | MGNX | 306 | Mid 2026 Data Could Decide MacroGenics’… | 2026-06-12 | 2026-07-17 | 35 | 3.14 | 5.25 | 67% | 3.96 | 5.08 | 4.56 | 28.28% | 15.15% | 15.15% | Missed |
| 194 | 2026-05-02 | OKUR | 182 | Cash Rich OnKure Awaits Fall Data Valid… | 2026-09-21 | 2026-11-06 | 46 | 4.75 | 8.50 | 79% | |||||||
| 193 | 2026-05-02 | NRSN | 27 | May Regulatory Clarity Could Decide Neu… | 2026-05-06 | 2026-05-29 | 23 | 0.9100 | 1.60 | 76% | 0.8979 | 0.9759 | 0.8214 | 8.69% | -8.52% | -8.52% | Missed |
| 192 | 2026-04-30 | TRAW | 13 | MHRA Decision Could Reawaken Traws’ Dee… | 2026-05-22 | 2026-06-17 | 26 | 1.42 | 3.20 | 125% | 1.49 | 1.72 | 0.7985 | 15.43% | -46.41% | Early Breakout | |
| 191 | 2026-04-30 | RNAZ | 5 | Phase 2a Clearance May Decide RNAZ’s Ne… | 2026-05-18 | 2026-06-26 | 39 | 8.21 | 14.50 | 77% | 6.17 | 7.14 | 5.05 | 15.72% | -18.15% | -18.15% | Missed |
| 190 | 2026-04-30 | INAB | 13 | Microcap IN8bio Could Reprice Sharply O… | 2026-05-20 | 2026-06-19 | 30 | 1.47 | 3.20 | 118% | 1.57 | 1.88 | 1.43 | 19.75% | -8.92% | -8.92% | Missed |
| 189 | 2026-04-30 | HIND | 15 | Phase 3 Clarity Could Awaken This Forgo… | 2026-05-20 | 2026-06-30 | 41 | 2.03 | 4.50 | 122% | 2.11 | 2.50 | 2.16 | 18.48% | 2.37% | 2.37% | Missed |
| 188 | 2026-04-30 | GTBP | 16 | GTB 5550 Clinical Launch May Spark GTBP… | 2026-06-08 | 2026-07-10 | 32 | 0.3199 | 0.8500 | 166% | 0.4252 | 0.5574 | 0.4250 | 31.09% | -0.05% | -0.05% | Missed |
| 187 | 2026-04-30 | CELZ | 4 | Final ADAPT Data Could Reprice Tiny Flo… | 2026-05-18 | 2026-06-30 | 43 | 2.26 | 4.25 | 88% | 2.23 | 2.49 | 1.15 | 11.66% | -48.43% | -48.43% | Missed |
| 186 | 2026-04-27 | BRTX | 9 | Depressed BRTX Awaits Its Next Real Cli… | 2026-06-08 | 2026-07-10 | 32 | 0.2308 | 0.6500 | 182% | 0.3620 | 0.4281 | 0.3753 | 18.26% | 3.67% | Early Breakout | |
| 185 | 2026-04-27 | COCP | 14 | ICAR Update Could Test Whether CDI 988 … | 2026-04-28 | 2026-05-06 | 8 | 1.43 | 2.40 | 68% | 1.39 | 1.48 | 1.41 | 6.46% | 1.44% | 1.44% | Missed |
| 184 | 2026-04-26 | OTLK | 207 | May FDA Dispute Ruling Could Decide OTL… | 2026-05-04 | 2026-05-22 | 18 | 0.3151 | 0.7500 | 138% | 0.2625 | 0.3700 | 0.3099 | 40.95% | 18.06% | 18.06% | Missed |
| 183 | 2026-04-21 | QTTB | 223 | Q32 Bio Faces Its Defining Mid 2026 Alo… | 2026-06-08 | 2026-07-10 | 32 | 6.41 | 12.50 | 95% | 12.03 | 13.99 | 12.92 | 16.29% | 7.4% | Early Breakout | |
| 182 | 2026-04-21 | IGC | 26 | CALMA Enrollment Finish Could Reawaken … | 2026-05-27 | 2026-07-10 | 44 | 0.3136 | 0.5200 | 66% | 0.2900 | 0.3144 | 0.2639 | 8.41% | -9% | -9% | Missed |
| 181 | 2026-04-21 | ELTX | 76 | ELTX Nears Binary Pancreatic Cancer Rea… | 2026-05-18 | 2026-06-26 | 39 | 12.11 | 19.00 | 57% | 9.57 | 16.00 | 4.02 | 67.19% | -57.99% | -57.99% | Missed |
| 180 | 2026-04-21 | ALLR | 21 | ALLR’s Next Rerating Likely Hinges On O… | 2026-06-10 | 2026-07-24 | 44 | 1.25 | 2.40 | 92% | 1.49 | 1.64 | 1.29 | 10% | -13.76% | -13.76% | Missed |
| 179 | 2026-04-18 | CING | 66 | May FDA Decision Could Redefine Cingula… | 2026-05-11 | 2026-06-05 | 25 | 5.45 | 11.50 | 111% | 4.96 | 5.30 | 4.50 | 6.85% | -9.37% | -9.37% | Missed |
| 178 | 2026-04-18 | NXTC | 6 | ASCO SIM0505 Data Could Reignite Tiny F… | 2026-05-22 | 2026-06-09 | 18 | 10.33 | 16.00 | 55% | 7.83 | 10.32 | 2.33 | 31.8% | -70.24% | -70.24% | Missed |
| 177 | 2026-04-17 | CVKD | 9 | Phase 3 Clarity Could Revive Battered M… | 2026-05-12 | 2026-06-12 | 31 | 4.85 | 8.50 | 75% | 5.19 | 5.89 | 3.70 | 13.4% | -28.71% | -28.71% | Missed |
| 176 | 2026-04-16 | KROS | 218 | Keros Faces Make Or Break DMD Launch Wi… | 2026-05-12 | 2026-06-12 | 31 | 11.72 | 16.50 | 41% | 11.65 | 12.01 | 10.15 | 3.09% | -12.88% | -12.88% | Missed |
| 175 | 2026-04-16 | MBRX | 17 | Mid 2026 AML Unblinding Could Redefine … | 2026-05-13 | 2026-06-30 | 48 | 2.40 | 5.50 | 129% | 2.14 | 3.55 | 3.40 | 65.89% | 58.87% | 58.87% | Missed |
| 174 | 2026-04-15 | KRRO | 183 | Korro’s Next AATD Nomination May Reigni… | 2026-05-18 | 2026-06-30 | 43 | 13.68 | 21.00 | 54% | 9.97 | 15.09 | 12.17 | 51.35% | 22.02% | 22.02% | Missed |
| 173 | 2026-04-13 | NRXP | 135 | Summer FDA Ketamine Decision Could Reaw… | 2026-06-22 | 2026-08-07 | 46 | 2.28 | 4.80 | 111% | 3.90 | 4.17 | 3.71 | 6.92% | -5% | Early Breakout | |
| 172 | 2026-04-12 | BIVI | 15 | BioVie’s Next Real Test Is The Mid 2026… | 2026-06-22 | 2026-07-17 | 25 | 1.35 | 3.80 | 181% | 1.94 | 2.12 | 1.92 | 9.28% | -1.03% | -1.03% | Missed |
| 171 | 2026-04-12 | CNTB | 138 | Midyear Seabreeze Data Could Decide CNT… | 2026-06-08 | 2026-07-24 | 46 | 2.82 | 5.50 | 95% | 2.20 | 2.31 | 2.27 | 5% | 3.18% | 3.18% | Missed |
| 170 | 2026-04-12 | VRCA | 118 | VP 315 Conference Data Could Ignite VRC… | 2026-05-08 | 2026-05-22 | 14 | 5.11 | 8.50 | 66% | 7.99 | 8.23 | 6.06 | 3% | -24.16% | Early Breakout | |
| 169 | 2026-04-11 | SPRO | 131 | Spero Therapeutics Nears Potential Brea… | 2026-06-10 | 2026-06-25 | 15 | 2.67 | 4.50 | 69% | 2.54 | 3.05 | 2.02 | 20.08% | -20.47% | -20.47% | Missed |
| 168 | 2026-04-03 | ENTX | 80 | Entera Bio Nears Major Catalyst With EB… | 2026-05-01 | 2026-12-31 | 244 | 1.26 | 3.50 | 178% | 1.10 | 2.78 | 1.63 | 152.72% | 47.78% | 47.78% | Missed |
| 167 | 2026-04-01 | PMN | 94 | ProMIS Set To Transform Alzheimer's Tre… | 2026-08-01 | 2026-12-31 | 152 | 13.00 | 19.00 | 46% | |||||||
| 166 | 2026-04-01 | TLPH | 9 | Talphera Nears Critical Trial Completio… | 2026-09-25 | 2026-10-10 | 15 | 0.7777 | 1.50 | 93% | |||||||
| 165 | 2026-04-01 | ONCY | 113 | Oncolytics Biotech Set For Breakout On … | 2026-12-20 | 2027-01-10 | 21 | 0.9301 | 2.50 | 169% | |||||||
| 164 | 2026-04-01 | MNOV | 65 | MediciNova Set For Surge With Imminent … | 2026-06-05 | 2026-09-30 | 117 | 1.42 | 3.50 | 146% | 1.31 | 1.37 | 1.28 | 4.58% | -2.29% | -2.29% | Missed |
| 163 | 2026-03-30 | BCTX | 27 | BriaCell Set For Breakout With Key Phas… | 2026-05-01 | 2026-07-31 | 91 | 3.75 | 12.00 | 220% | 4.18 | 4.34 | 3.05 | 3.83% | -27.03% | -27.03% | Missed |
| 162 | 2026-03-30 | ATHE | 84 | Alterity Therapeutics: Nearing Phase 3 … | 2026-06-01 | 2026-07-31 | 60 | 3.16 | 7.00 | 122% | 4.02 | 5.30 | 4.89 | 31.97% | 21.76% | 21.76% | Missed |
| 161 | 2026-03-27 | CTXR | 15 | Citius Pharmaceuticals Poised For Growt… | 2026-07-01 | 2026-12-31 | 183 | 0.6942 | 2.00 | 188% | |||||||
| 160 | 2026-03-27 | ALGS | 34 | Potential Breakthrough For Aligos Thera… | 2026-04-20 | 2026-07-31 | 102 | 7.04 | 28.00 | 298% | 6.51 | 6.91 | 5.48 | 6.14% | -15.82% | -15.82% | Missed |
| 159 | 2026-03-26 | BFRI | 7 | Biofrontera Nears Potential Breakthroug… | 2026-08-30 | 2026-10-15 | 46 | 0.8098 | 1.50 | 85% | |||||||
| 158 | 2026-03-25 | AGEN | 126 | Agenus Poised For Breakthrough With Upc… | 2026-04-15 | 2026-04-30 | 15 | 3.56 | 6.50 | 83% | 4.83 | 5.08 | 3.91 | 5.18% | -19.05% | -19.05% | Missed |
| 157 | 2026-03-24 | RNAC | 277 | Cartesian Poised For Breakout With Upco… | 2026-06-01 | 2026-12-31 | 213 | 6.07 | 25.00 | 312% | 6.92 | 11.00 | 9.07 | 58.96% | 31% | 31% | Missed |
| 156 | 2026-03-23 | DTIL | 188 | Precision BioSciences Set For Breakout … | 2026-05-01 | 2026-07-31 | 91 | 6.52 | 15.00 | 130% | 7.28 | 8.59 | 7.52 | 17.99% | 3.3% | 3.3% | Missed |
| 155 | 2026-03-18 | CADL | 717 | Promising Phase 3 Data Could Propel Can… | 2026-05-15 | 2026-06-30 | 46 | 5.17 | 10.50 | 103% | 8.77 | 9.99 | 9.55 | 13.91% | 8.89% | 8.89% | Missed |
| 154 | 2026-03-18 | ACOG | 145 | Alpha Cognition Set For Growth With Upc… | 2026-09-25 | 2026-12-31 | 97 | 5.76 | 14.50 | 152% | |||||||
| 153 | 2026-03-13 | CLRB | 20 | Cellectar Poised For Breakout With Key … | 2026-06-01 | 2026-12-31 | 213 | 3.20 | 7.00 | 119% | 2.97 | 3.14 | 2.50 | 5.72% | -15.79% | -15.79% | Missed |
| 152 | 2026-03-08 | ALXO | 275 | ALX Oncology Set For Breakout With Key … | 2026-08-01 | 2026-12-31 | 152 | 2.21 | 4.50 | 104% | |||||||
| 151 | 2026-03-06 | LXRX | 1130 | Lexicon Gears Up For Breakout With Key … | 2026-06-03 | 2026-12-31 | 211 | 1.64 | 3.50 | 113% | 1.85 | 2.53 | 2.50 | 36.76% | 34.86% | 34.86% | Missed |
| 150 | 2026-03-05 | VSTM | 332 | Verastem Set To Rise On Promising Cance… | 2026-05-01 | 2026-08-31 | 122 | 6.15 | 16.57 | 169% | 5.84 | 6.10 | 3.59 | 4.45% | -38.53% | -38.53% | Missed |
| 149 | 2026-03-03 | MRKR | 22 | Marker Therapeutics Poised For Breakout… | 2026-03-28 | 2026-05-30 | 63 | 1.40 | 4.50 | 221% | 1.24 | 1.79 | 1.57 | 44.35% | 26.61% | 26.61% | Missed |
| 148 | 2026-02-27 | SNES | 10 | SenesTech Set For Growth With Global Re… | 2026-04-01 | 2026-07-31 | 121 | 2.28 | 3.50 | 54% | 1.68 | 2.07 | 1.55 | 23.21% | -7.74% | -7.74% | Missed |
| 147 | 2026-02-07 | KALV | 1440 | Sebetralstat Adoption Could Catapult Ka… | 2026-06-01 | 2026-07-31 | 60 | 14.90 | 33.00 | 121% | 26.94 | 27.00 | 27.00 | 0.22% | 0.22% | 0.22% | Missed |
| 146 | 2026-01-24 | KPTI | 231 | Karyopharm Set For Breakout With Key 20… | 2026-02-20 | 2026-06-30 | 130 | 6.59 | 15.33 | 133% | 9.67 | 10.99 | 9.71 | 13.65% | 0.41% | 0.41% | Missed |
| 145 | 2026-01-23 | CRVO | 47 | CervoMed Set For Breakthrough With Phas… | 2026-07-01 | 2026-12-31 | 183 | 6.28 | 18.00 | 187% | |||||||
| 144 | 2026-01-23 | TNXP | 211 | Tonix Pharma Set For Breakthrough With … | 2026-02-01 | 2026-08-31 | 211 | 19.01 | 25.00 | 32% | 17.21 | 18.19 | 12.78 | 5.69% | -25.73% | -25.73% | Missed |
| 143 | 2026-01-21 | CHRS | 231 | Coherus Oncology Set For Breakout Amid … | 2026-01-27 | 2026-06-30 | 154 | 1.64 | 2.50 | 52% | 2.51 | 2.62 | 1.47 | 4.22% | -41.63% | Early Breakout | |
| 142 | 2026-01-20 | ARTL | 4 | Artelo Biosciences Set For Breakout On … | 2026-02-01 | 2026-03-31 | 58 | 5.13 | 10.50 | 105% | 4.89 | 19.91 | 7.58 | 307.16% | 55.01% | 114.72% | Breakout |
| 141 | 2026-01-20 | XNCR | 1120 | Xencor Poised For Growth With Pivotal X… | 2026-02-01 | 2026-05-30 | 118 | 12.79 | 18.50 | 45% | 12.11 | 14.54 | 11.88 | 20.07% | -1.9% | -1.9% | Missed |
| 140 | 2026-01-16 | PRTA | 525 | Prothena Set For Breakthrough With Key … | 2026-02-01 | 2026-08-31 | 211 | 9.35 | 14.00 | 50% | 8.91 | 11.80 | 9.67 | 32.44% | 8.53% | 8.53% | Missed |
| 139 | 2026-01-15 | HOTH | 26 | Promising Therapeutics Poised For Clini… | 2026-01-25 | 2026-03-30 | 64 | 1.08 | 2.50 | 131% | 1.04 | 1.26 | 0.7701 | 21.15% | -25.95% | -25.95% | Missed |
| 138 | 2026-01-14 | CDXS | 217 | Codexis Set To Transform RNAi Therapeut… | 2026-02-15 | 2026-06-15 | 120 | 1.71 | 3.50 | 105% | 1.21 | 2.98 | 2.49 | 146.28% | 105.79% | 105.79% | Missed |
| 137 | 2026-01-13 | CGEM | 1130 | Cullinan Therapeutics Set For Breakthro… | 2026-03-01 | 2026-12-31 | 305 | 10.73 | 29.50 | 175% | 15.99 | 19.43 | 18.17 | 21.51% | 13.6% | 13.6% | Missed |
| 136 | 2026-01-13 | WVE | 1120 | Wave Life Sciences: Poised For Breakout… | 2026-01-20 | 2026-03-26 | 65 | 13.91 | 22.00 | 58% | 13.82 | 15.47 | 6.20 | 11.94% | -55.14% | -55.14% | Missed |
| 135 | 2025-11-19 | CYPH | 168 | Cypherpunk Eyes Growth With Strategic S… | 2025-12-10 | 2025-12-20 | 10 | 2.97 | 5.50 | 85% | 1.44 | 1.65 | 1.30 | 14.58% | -9.72% | -9.72% | Missed |
| 134 | 2025-10-12 | IBIO | 83 | Strategic Shift Poised To Propel IBio's… | 2025-11-01 | 2026-05-01 | 181 | 0.7913 | 1.50 | 90% | 1.76 | 3.82 | 1.59 | 117.05% | -9.66% | Early Breakout | |
| 133 | 2025-10-12 | AEMD | 5 | Aethlon Medical Poised For Breakthrough… | 2025-11-01 | 2026-06-30 | 241 | 6.93 | 30.00 | 333% | 4.92 | 5.24 | 0.9073 | 6.5% | -81.56% | -81.56% | Missed |
| 132 | 2025-09-19 | VRCA | 118 | Verrica Set For Surge As Phase 3 Trials… | 2025-10-25 | 2026-01-10 | 77 | 4.04 | 6.50 | 61% | 3.76 | 9.82 | 7.95 | 161.2% | 111.3% | 72.87% | Breakout |
| 131 | 2025-09-14 | ATNM | 31 | Actinium Poised For Growth With Upcomin… | 2025-10-01 | 2025-12-31 | 91 | 1.63 | 2.50 | 53% | 1.60 | 1.74 | 1.36 | 8.75% | -15% | -15% | Missed |
| 130 | 2025-09-10 | CLRB | 20 | Cellectar Set For Regulatory Breakthrou… | 2025-09-25 | 2025-10-10 | 15 | 5.00 | 12.50 | 150% | 5.75 | 6.52 | 4.64 | 13.39% | -19.3% | -19.3% | Missed |
| 129 | 2025-09-10 | MGNX | 306 | MacroGenics Set For Potential Upswing A… | 2025-09-20 | 2025-11-30 | 71 | 1.72 | 4.00 | 133% | 1.73 | 2.15 | 1.53 | 24.28% | -11.56% | -11.56% | Missed |
| 128 | 2025-09-10 | DMAC | 353 | DiaMedica Poised For Breakthrough With … | 2026-02-01 | 2026-06-30 | 149 | 7.21 | 12.33 | 71% | 8.18 | 9.04 | 6.30 | 10.51% | -22.98% | -22.98% | Missed |
| 127 | 2025-09-10 | LXRX | 1130 | Lexicon Poised For Growth With Promisin… | 2025-09-15 | 2026-01-15 | 122 | 1.13 | 2.50 | 121% | 1.12 | 1.66 | 1.28 | 48.21% | 14.29% | 14.29% | Missed |
| 126 | 2025-09-10 | CDXS | 217 | Codexis Gears Up For Major Breakthrough… | 2025-10-25 | 2025-11-15 | 21 | 2.45 | 8.00 | 227% | 2.60 | 2.82 | 1.65 | 8.46% | -36.73% | -36.73% | Missed |
| 125 | 2025-07-29 | IMDX | 86 | IMDX Set For Surge As FDA Decision Near… | 2025-11-01 | 2025-12-31 | 60 | 2.79 | 6.50 | 133% | 6.12 | 8.51 | 7.50 | 39.05% | 22.55% | 6.21% | Breakout |
| 124 | 2025-07-28 | ADAP | 64 | Adaptimmune Set For Breakout With Pendi… | 2025-07-31 | 2025-08-05 | 5 | 0.1000 | 1.50 | 1400% | 0.0803 | 0.1200 | 0.0951 | 49.44% | 18.43% | 18.43% | Missed |
| 123 | 2025-07-08 | ARTL | 4 | Artelo Poised For Breakout With Upcomin… | 2025-08-01 | 2025-12-31 | 152 | 14.32 | 25.00 | 75% | 10.20 | 12.16 | 1.22 | 19.22% | -88.04% | -88.04% | Missed |
| 122 | 2025-07-08 | BFRI | 7 | Biofrontera Set For Breakout Amid Promi… | 2025-07-28 | 2025-12-31 | 156 | 0.6949 | 1.20 | 73% | 1.07 | 1.19 | 0.5700 | 11.21% | -46.73% | -46.73% | Missed |
| 121 | 2025-07-08 | DRMA | 5 | Dermata Set For Breakout On Imminent FD… | 2025-07-15 | 2025-08-30 | 46 | 6.95 | 30.00 | 332% | 7.30 | 7.78 | 5.74 | 6.53% | -21.41% | -21.41% | Missed |
| 120 | 2025-07-08 | LPTX | 12 | Leap Therapeutics Poised For Breakout W… | 2025-09-01 | 2025-12-31 | 121 | 0.2838 | 5.50 | 1838% | 0.2945 | 3.70 | 1.16 | 1156.33% | 293.89% | 293.89% | Missed |
| 119 | 2025-07-08 | EQ | 193 | Equillium Set For Significant Upswing A… | 2025-07-15 | 2025-08-30 | 46 | 0.3190 | 1.25 | 292% | 0.3810 | 2.26 | 1.74 | 493.18% | 356.69% | 228.08% | Breakout |
| 118 | 2025-07-08 | ENFY | 18 | Enlightify Set To Transform With Blockc… | 2025-08-01 | 2025-08-31 | 30 | 1.10 | 1.65 | 50% | 0.9099 | 1.04 | 1.01 | 14.3% | 11% | 11% | Missed |
| 117 | 2025-07-08 | TLPH | 9 | Talphera Nears Potential Breakthrough W… | 2025-09-25 | 2025-12-31 | 97 | 0.4630 | 1.20 | 159% | 0.9021 | 1.57 | 1.14 | 74.04% | 26.37% | 33.02% | Breakout |
| 116 | 2025-07-07 | BTAI | 12 | Anticipating Breakout: BioXcel's SERENI… | 2025-07-15 | 2025-09-30 | 77 | 1.90 | 4.50 | 137% | 1.90 | 8.08 | 2.56 | 325.26% | 34.74% | 136.84% | Breakout |
| 115 | 2025-07-07 | IRD | 326 | Opus Genetics Set For Breakthrough With… | 2025-10-01 | 2025-12-31 | 91 | 0.9921 | 3.50 | 253% | 1.80 | 2.59 | 2.01 | 43.93% | 11.67% | 11.67% | Missed |
| 114 | 2025-07-07 | TTNP | 6 | Titan Pharma Poised For Breakout On Cli… | 2025-09-05 | 2025-12-25 | 111 | 4.45 | 7.50 | 69% | 4.23 | 4.80 | 4.61 | 13.48% | 8.98% | 8.98% | Missed |
| 113 | 2025-07-07 | ATNF | 5 | 180 Life Sciences Poised For Strategic … | 2025-07-15 | 2025-08-30 | 46 | 8.00 | 15.00 | 88% | 8.94 | 174.60 | 28.10 | 1852.8% | 214.28% | 67.77% | Breakout |
| 112 | 2025-07-07 | VERU | 48 | Veru Set To Surge On Potential FDA Appr… | 2025-09-25 | 2025-10-10 | 15 | 6.07 | 25.00 | 312% | 3.59 | 4.59 | 3.93 | 27.86% | 9.47% | 9.47% | Missed |
| 111 | 2025-07-07 | VIVS | 3 | VivoSim Labs Set To Transform Drug Test… | 2025-08-01 | 2025-12-31 | 152 | 1.57 | 3.50 | 123% | 1.85 | 5.30 | 1.81 | 186.49% | -2.16% | 89.19% | Breakout |
| 110 | 2025-07-07 | IMDX | 86 | Insight Molecular Diagnostics Nears Bre… | 2025-07-29 | 2025-08-29 | 31 | 2.85 | 5.00 | 75% | |||||||
| 109 | 2025-07-07 | TRAW | 13 | Traws Pharma Nears Key Clinical Catalys… | 2025-09-25 | 2025-10-10 | 15 | 1.45 | 3.50 | 141% | 1.88 | 3.27 | 3.01 | 73.67% | 60.11% | 60.11% | Missed |
| 108 | 2025-07-07 | CELU | 18 | Celularity Set To Surge On Imminent FDA… | 2025-09-25 | 2025-10-10 | 15 | 1.98 | 5.50 | 178% | 2.04 | 2.27 | 2.05 | 11.27% | 0.49% | 0.49% | Missed |
| 107 | 2025-07-07 | DTIL | 188 | Promising FDA Designation Poised To Pro… | 2025-12-28 | 2026-01-31 | 34 | 4.34 | 12.00 | 176% | 4.30 | 4.61 | 3.96 | 7.21% | -7.91% | -7.91% | Missed |
| 106 | 2025-07-07 | ATRA | 94 | Atara Biotherapeutics Poised For Breakt… | 2025-08-20 | 2025-09-30 | 41 | 8.47 | 14.00 | 65% | 11.76 | 14.91 | 14.33 | 26.75% | 21.85% | 19.05% | Breakout |
| 105 | 2025-07-07 | VRCA | 118 | Verrica Poised For Breakout With Pivota… | 2025-10-01 | 2025-12-31 | 91 | 7.06 | 40.00 | 467% | |||||||
| 104 | 2025-07-07 | MRKR | 22 | Marker Therapeutics Poised For Breakout… | 2025-07-12 | 2025-08-05 | 24 | 1.60 | 2.80 | 75% | 1.58 | 4.07 | 1.25 | 157.59% | -20.89% | 77.22% | Breakout |
| 103 | 2025-07-07 | SNES | 10 | SenesTech Set For Growth With Global Ex… | 2025-10-01 | 2026-01-31 | 122 | 5.14 | 10.00 | 95% | 4.07 | 4.45 | 1.85 | 9.34% | -54.55% | -54.55% | Missed |
| 102 | 2025-07-07 | HYPD | 46 | Hyperion DeFi Aims For Breakthrough In … | 2025-09-20 | 2025-10-25 | 35 | 14.36 | 22.50 | 57% | 10.16 | 11.89 | 7.74 | 17.03% | -23.82% | -23.82% | Missed |
| 101 | 2025-07-07 | RPTX | 113 | Repare Therapeutics Poised For Breakout… | 2025-09-25 | 2025-11-30 | 66 | 1.44 | 2.80 | 94% | 1.67 | 2.30 | 2.18 | 37.72% | 30.54% | 30.54% | Missed |
| 100 | 2025-07-07 | SNGX | 6 | Soligenix Set For Breakthrough With HyB… | 2025-10-01 | 2026-03-31 | 181 | 1.20 | 4.50 | 275% | 1.24 | 1.97 | 1.18 | 58.87% | -4.84% | Early Breakout | |
| 99 | 2025-07-07 | MTNB | 4 | Matinas BioPharma Set To Surge On Pivot… | 2025-09-25 | 2025-10-10 | 15 | 0.9172 | 1.45 | 58% | 1.88 | 1.99 | 1.71 | 5.85% | -9.04% | Early Breakout | |
| 98 | 2025-07-07 | STEM | 56 | Stem Inc: Poised For Breakout With Stra… | 2025-07-15 | 2025-08-15 | 31 | 8.61 | 12.00 | 39% | 8.68 | 19.48 | 14.78 | 124.42% | 70.28% | 38.25% | Breakout |
| 97 | 2025-07-07 | INM | 10 | InMed Set For Breakout Amid Promising A… | 2025-08-01 | 2025-09-30 | 60 | 2.91 | 5.50 | 89% | 2.39 | 2.45 | 2.19 | 2.51% | -8.37% | -8.37% | Missed |
| 96 | 2025-07-07 | RKDA | 6 | Arkadia Biosciences Set For Growth Post… | 2025-08-25 | 2025-09-10 | 16 | 4.65 | 6.50 | 40% | 3.96 | 4.09 | 3.18 | 3.28% | -19.7% | -19.7% | Missed |
| 95 | 2025-07-07 | CYCN | 14 | Cyclerion Set For Breakout With Key Cli… | 2025-11-01 | 2026-03-01 | 120 | 3.36 | 7.50 | 123% | 1.86 | 2.28 | 1.35 | 22.58% | -27.42% | -27.42% | Missed |
| 94 | 2025-07-07 | STRO | 506 | Sutro Biopharma Set For Breakthrough Wi… | 2025-12-20 | 2026-01-15 | 26 | 7.63 | 22.00 | 188% | 10.37 | 13.30 | 13.07 | 28.24% | 26.04% | 26.04% | Missed |
| 93 | 2025-07-07 | HOOK | 15 | HOOKIPA Set For Breakout On Strong Clin… | 2025-12-01 | 2026-01-01 | 31 | 1.23 | 2.75 | 124% | 0.8631 | 0.9100 | 0.8930 | 5.43% | 3.46% | 3.46% | Missed |
| 92 | 2025-07-07 | CLRB | 20 | Promising Outlook For Cellectar Amid Cl… | 2025-07-25 | 2025-08-15 | 21 | 4.80 | 12.00 | 150% | |||||||
| 91 | 2025-07-07 | STTK | 494 | Shattuck Labs Poised For Breakout With … | 2025-08-01 | 2025-09-30 | 60 | 0.8334 | 1.50 | 80% | 0.7320 | 2.48 | 2.39 | 238.8% | 226.5% | 104.92% | Breakout |
| 90 | 2025-07-07 | CRIS | 13 | Curis Poised For Breakout With Promisin… | 2025-09-25 | 2025-10-10 | 15 | 1.81 | 2.90 | 60% | 1.64 | 1.74 | 1.52 | 6.1% | -7.32% | -7.32% | Missed |
| 89 | 2025-07-07 | YMAB | 204 | Y MAbs Poised For Breakout With Upcomin… | 2025-09-20 | 2025-10-20 | 30 | 4.30 | 14.58 | 239% | |||||||
| 88 | 2025-07-07 | XBIO | 7 | Xenetic Poised For Breakout With Upcomi… | 2025-11-01 | 2025-12-31 | 60 | 3.70 | 5.50 | 49% | 3.12 | 3.35 | 2.17 | 7.37% | -30.45% | -30.45% | Missed |
| 87 | 2025-07-07 | DARE | 31 | Dare Bioscience Nears Potential FDA App… | 2025-10-01 | 2025-12-31 | 91 | 2.40 | 6.50 | 171% | 2.15 | 2.54 | 1.93 | 18.14% | -10.23% | -10.23% | Missed |
| 86 | 2025-07-07 | GEVO | 316 | Gevo Set For Breakout As Green Fuel Inn… | 2025-07-20 | 2025-08-10 | 21 | 1.50 | 2.80 | 87% | 1.48 | 1.60 | 1.18 | 8.11% | -20.27% | -20.27% | Missed |
| 85 | 2025-07-07 | AMS | 16 | American Shared Set To Surge On New Med… | 2025-08-01 | 2025-12-31 | 152 | 2.49 | 3.50 | 41% | 2.50 | 3.11 | 2.11 | 24.4% | -15.6% | -15.6% | Missed |
| 84 | 2025-07-07 | SYBX | 14 | Synlogic Set For Breakthrough With Upco… | 2025-08-01 | 2025-10-15 | 75 | 1.18 | 2.50 | 112% | 1.48 | 1.79 | 1.68 | 20.95% | 13.51% | 13.51% | Missed |
| 83 | 2025-07-07 | FBIO | 92 | Fortress Biotech Set For Breakthrough W… | 2025-09-20 | 2025-12-31 | 102 | 1.88 | 3.50 | 86% | 4.00 | 4.20 | 3.66 | 5% | -8.5% | Early Breakout | |
| 82 | 2025-07-07 | CUE | 103 | "Cue Biopharma Set For Breakthrough Wit… | 2025-11-01 | 2026-01-31 | 91 | 0.6952 | 2.50 | 260% | 0.7175 | 0.8500 | 0.3348 | 18.47% | -53.34% | -53.34% | Missed |
| 81 | 2025-07-07 | ORGO | 464 | Organogenesis Set For Growth With Upcom… | 2025-08-01 | 2025-08-31 | 30 | 4.25 | 6.50 | 53% | 4.51 | 5.17 | 5.15 | 14.63% | 14.19% | 14.19% | Missed |
| 80 | 2025-07-07 | CHRS | 231 | Coherus Oncology: Poised For Breakthrou… | 2025-08-01 | 2025-11-30 | 121 | 0.8100 | 2.50 | 209% | 0.8778 | 1.89 | 1.36 | 115.31% | 54.93% | 54.93% | Missed |
| 79 | 2025-07-07 | MRSN | 37 | Mersana Poised For Breakout With Promis… | 2025-10-01 | 2025-12-31 | 91 | 7.23 | 37.50 | 419% | 7.94 | 29.39 | 28.93 | 270.15% | 264.36% | 264.36% | Missed |
| 78 | 2025-07-07 | NERV | 204 | Minerva Set For Breakout With Upcoming … | 2025-08-01 | 2025-09-30 | 60 | 1.65 | 3.50 | 112% | 1.91 | 2.60 | 2.11 | 35.95% | 10.07% | 10.07% | Missed |
| 77 | 2025-07-07 | RGNX | 542 | REGENXBIO Set For Breakthrough With Imp… | 2025-10-01 | 2026-01-31 | 122 | 8.74 | 35.00 | 300% | 9.77 | 16.19 | 11.16 | 65.71% | 14.23% | 14.23% | Missed |
| 76 | 2025-07-07 | ARCT | 196 | Arcturus Therapeutics: Poised For Break… | 2025-08-01 | 2025-11-30 | 121 | 13.78 | 28.00 | 103% | 12.30 | 24.17 | 6.79 | 96.5% | -44.8% | -44.8% | Missed |
| 75 | 2025-07-07 | NATR | 273 | Nature's Sunshine Set For Growth Surge … | 2025-07-15 | 2025-09-30 | 77 | 15.59 | 18.50 | 19% | 14.95 | 17.64 | 15.52 | 17.99% | 3.81% | 3.81% | Missed |
| 74 | 2025-07-07 | ALEC | 207 | Alector Eyes Breakthrough With Pivotal … | 2025-10-20 | 2025-12-31 | 72 | 1.51 | 3.50 | 132% | 3.31 | 3.34 | 1.56 | 0.76% | -52.87% | -52.87% | Missed |
| 73 | 2025-07-07 | EDIT | 437 | Editas Medicine Set For Breakout On Upc… | 2025-11-28 | 2025-12-15 | 17 | 2.57 | 4.20 | 63% | 2.41 | 2.70 | 2.44 | 12.03% | 1.24% | 1.24% | Missed |
| 72 | 2025-07-07 | ASRT | 61 | Assertio Faces Turnaround Challenges Am… | 2025-08-01 | 2025-08-31 | 30 | 0.6530 | 1.00 | 53% | 10.69 | 13.05 | 12.53 | 22.11% | 17.21% | Early Breakout | |
| 71 | 2025-07-07 | VYGR | 217 | Voyager Poised For Breakthrough With No… | 2025-10-01 | 2026-04-30 | 211 | 3.20 | 8.50 | 166% | 4.68 | 5.55 | 3.73 | 18.59% | -20.3% | -20.3% | Missed |
| 70 | 2025-07-06 | DERM | 162 | Journey Medical Set For Surge With Emro… | 2025-07-10 | 2025-09-30 | 82 | 7.10 | 9.75 | 37% | 7.22 | 8.90 | 7.12 | 23.27% | -1.39% | -1.39% | Missed |
| 69 | 2025-07-06 | JAGX | 2 | Jaguar Health Poised For Breakthrough W… | 2025-11-01 | 2026-05-31 | 211 | 2.58 | 5.75 | 123% | 58.86 | 66.82 | 3.55 | 13.51% | -93.97% | Early Breakout | |
| 68 | 2025-07-06 | NBY | 52 | Investor Alert: NovaBay's Pivotal Decis… | 2025-08-01 | 2025-08-31 | 30 | 3.15 | 6.25 | 99% | 2.97 | 10.65 | 8.90 | 258.89% | 199.92% | 110.61% | Breakout |
| 67 | 2025-07-06 | CPHI | 6 | China Pharma Poised For Growth With New… | 2025-08-01 | 2025-09-30 | 60 | 1.84 | 2.50 | 36% | 1.64 | 2.03 | 1.95 | 23.77% | 18.9% | 18.9% | Missed |
| 66 | 2025-07-06 | ORMP | 191 | Oramed Set To Transform Diabetes Treatm… | 2025-11-20 | 2025-12-15 | 25 | 2.18 | 3.50 | 61% | 2.42 | 3.20 | 3.08 | 32.23% | 27.27% | 27.27% | Missed |
| 65 | 2025-07-06 | SPRO | 131 | Spero Therapeutics Nears Potential FDA … | 2025-08-25 | 2025-09-10 | 16 | 2.91 | 5.50 | 89% | 1.85 | 2.20 | 1.94 | 18.65% | 4.86% | 4.86% | Missed |
| 64 | 2025-07-06 | CTMX | 740 | CytomX Set To Surge On Promising Cancer… | 2025-07-15 | 2025-08-15 | 31 | 2.50 | 5.50 | 120% | 2.40 | 2.50 | 1.91 | 4.17% | -20.42% | -20.42% | Missed |
| 63 | 2025-07-06 | ETON | 382 | Eton Pharmaceuticals Set For Breakout A… | 2025-07-12 | 2025-08-25 | 44 | 14.45 | 29.67 | 105% | 14.54 | 17.70 | 17.09 | 21.7% | 17.54% | 17.54% | Missed |
| 62 | 2025-07-06 | FF | 170 | FutureFuel: Strategic Shifts Poised For… | 2025-08-07 | 2025-08-15 | 8 | 4.17 | 5.50 | 32% | 3.85 | 3.94 | 3.61 | 2.21% | -6.23% | -6.23% | Missed |
| 61 | 2025-07-06 | AGEN | 126 | Agenus Set For Breakout On Promising Ph… | 2025-11-25 | 2025-12-10 | 15 | 6.07 | 9.50 | 57% | 4.38 | 4.64 | 4.09 | 5.94% | -6.62% | -6.62% | Missed |
| 60 | 2025-07-06 | ICCC | 89 | ImmuCell Poised For Growth With Pending… | 2025-10-01 | 2025-12-31 | 91 | 6.40 | 8.50 | 33% | 6.60 | 7.12 | 6.15 | 7.88% | -6.82% | -6.82% | Missed |
| 59 | 2025-07-06 | APVO | 6 | Aptevo Set To Transform With Upcoming A… | 2025-11-01 | 2025-12-15 | 44 | 3.04 | 6.50 | 114% | 26.46 | 28.08 | 18.72 | 6.12% | -29.25% | Early Breakout | |
| 58 | 2025-07-06 | TXMD | 14 | TherapeuticsMD: Royalty Strategy Set To… | 2025-10-27 | 2025-11-10 | 14 | 1.18 | 1.75 | 48% | 1.31 | 1.46 | 1.35 | 11.31% | 3.05% | 3.05% | Missed |
| 57 | 2025-07-06 | MTEX | 18 | Mannatech Gears Up For Strategic Growth… | 2025-08-01 | 2025-09-30 | 60 | 9.20 | 15.00 | 63% | 8.20 | 10.85 | 9.95 | 32.32% | 21.28% | 21.28% | Missed |
| 56 | 2025-07-06 | FTK | 441 | Flotek Poised For Breakout On Earnings … | 2025-07-10 | 2025-08-07 | 28 | 14.84 | 18.00 | 21% | 14.02 | 14.32 | 12.70 | 2.16% | -9.42% | -9.42% | Missed |
| 55 | 2025-07-06 | ADAP | 64 | Adaptimmune Set For Breakout With Pendi… | 2025-07-30 | 2025-08-20 | 21 | 0.2500 | 1.50 | 500% | |||||||
| 54 | 2025-07-06 | GPRE | 394 | Green Plains Poised For Growth With Sus… | 2025-07-20 | 2025-08-20 | 31 | 6.98 | 9.50 | 36% | 8.18 | 9.44 | 7.62 | 15.34% | -6.85% | -6.85% | Missed |
| 53 | 2025-07-06 | CPIX | 50 | Promising Clinical Developments Propel … | 2025-09-25 | 2025-12-15 | 81 | 3.15 | 5.25 | 67% | 3.03 | 3.69 | 2.97 | 21.93% | -1.82% | -1.82% | Missed |
| 52 | 2025-07-06 | PBYI | 413 | Puma Biotech Set For Gain Amid Promisin… | 2025-09-25 | 2025-10-10 | 15 | 3.58 | 4.50 | 26% | 4.70 | 5.45 | 5.12 | 15.85% | 8.94% | Early Breakout | |
| 51 | 2025-07-06 | TENX | 687 | Tenax Poised For Breakout With Pivotal … | 2025-12-01 | 2026-06-30 | 211 | 5.81 | 12.00 | 107% | 9.07 | 18.38 | 12.98 | 102.65% | 43.11% | 32.3% | Breakout |
| 50 | 2025-07-06 | RIGL | 716 | Rigel Poised For Breakout With Impendin… | 2025-07-10 | 2025-08-15 | 36 | 18.93 | 25.50 | 35% | 19.60 | 39.68 | 39.51 | 102.45% | 101.58% | 30.1% | Breakout |
| 49 | 2025-07-06 | IRWD | 126 | Ironwood Gears Up For Apraglutide NDA, … | 2025-07-20 | 2025-10-31 | 103 | 0.7660 | 1.20 | 57% | 0.7634 | 1.94 | 1.92 | 154.13% | 151.51% | 57.19% | Breakout |
| 48 | 2025-07-06 | XOMA | 529 | XOMA Set For Growth With Strategic Turn… | 2025-08-01 | 2025-09-30 | 60 | 26.96 | 35.00 | 30% | 24.77 | 38.75 | 38.54 | 56.44% | 55.59% | 41.3% | Breakout |
| 47 | 2025-07-06 | PRPH | 14 | ProPhase Labs Poised For Breakout With … | 2025-12-18 | 2026-01-15 | 28 | 4.19 | 10.00 | 139% | 1.05 | 1.84 | 0.1712 | 74.98% | -83.71% | -83.71% | Missed |
| 46 | 2025-07-06 | EBS | 346 | Emergent BioSolutions Set For Breakout … | 2025-11-01 | 2025-12-31 | 60 | 6.99 | 10.50 | 50% | 10.49 | 12.95 | 12.36 | 23.45% | 17.83% | 0.1% | Breakout |
| 45 | 2025-07-04 | ATNM | 31 | Actinium Set For Breakout Amid Pivotal … | 2025-07-20 | 2025-08-15 | 26 | 1.44 | 3.50 | 143% | |||||||
| 44 | 2025-07-04 | PLX | 185 | Protalix Poised For Breakout With Upcom… | 2025-07-20 | 2025-08-10 | 21 | 1.54 | 2.50 | 62% | 1.52 | 1.64 | 1.54 | 7.57% | 1.32% | 1.32% | Missed |
| 43 | 2025-07-04 | CRBP | 162 | Corbus Pharmaceuticals: Poised For Brea… | 2025-09-25 | 2026-03-30 | 186 | 7.71 | 15.00 | 95% | 12.14 | 20.56 | 8.60 | 69.36% | -29.16% | 23.56% | Breakout |
| 42 | 2025-07-04 | CVM | 19 | Multikine Nears Approval, Cel Sci Poise… | 2025-10-01 | 2026-01-31 | 122 | 2.49 | 12.00 | 382% | 9.94 | 10.83 | 5.80 | 8.95% | -41.65% | -41.65% | Missed |
| 41 | 2025-07-04 | PULM | 6 | Strategic Merger And Clinical Advances … | 2025-07-10 | 2025-08-15 | 36 | 6.53 | 8.50 | 30% | 6.44 | 6.83 | 4.71 | 6.06% | -26.86% | -26.86% | Missed |
| 40 | 2025-07-04 | OGEN | 3 | Oragenics Set For Breakout Amid Promisi… | 2025-12-25 | 2026-04-01 | 97 | 1.53 | 4.50 | 194% | 0.8590 | 1.11 | 0.5500 | 29.22% | -35.97% | -35.97% | Missed |
| 39 | 2025-07-04 | SCYX | 29 | SCYNEXIS Set For Breakout Amid Promisin… | 2025-11-01 | 2025-12-31 | 60 | 0.7314 | 2.50 | 242% | 0.6387 | 0.7300 | 0.6324 | 14.29% | -0.99% | -0.99% | Missed |
| 38 | 2025-07-04 | LPCN | 20 | Lipocine Eyes Breakthrough With Upcomin… | 2025-10-01 | 2025-11-30 | 60 | 3.10 | 8.50 | 174% | 2.97 | 3.59 | 3.44 | 20.88% | 15.82% | 15.82% | Missed |
| 37 | 2025-07-04 | FGEN | 21 | FibroGen Poised For Recovery With Key T… | 2025-07-25 | 2025-08-05 | 11 | 5.61 | 9.00 | 60% | 7.45 | 7.56 | 6.91 | 1.48% | -7.25% | -7.25% | Missed |
| 36 | 2025-07-04 | MEIP | 15 | MEI Pharma Poised For Breakout With Upc… | 2025-09-25 | 2025-10-30 | 35 | 2.68 | 5.50 | 105% | 2.54 | 2.97 | 1.95 | 16.93% | -23.23% | -23.23% | Missed |
| 35 | 2025-07-04 | XNCR | 1120 | Xencor Poised For Breakout With Promisi… | 2025-12-20 | 2026-01-10 | 21 | 8.42 | 15.00 | 78% | 15.97 | 16.17 | 13.89 | 1.25% | -13.02% | Early Breakout | |
| 34 | 2025-07-04 | KPTI | 231 | Karyopharm Set For Potential Breakout A… | 2025-11-20 | 2025-12-15 | 25 | 4.39 | 8.50 | 94% | 5.76 | 7.48 | 6.71 | 29.86% | 16.49% | 16.49% | Missed |
| 33 | 2025-07-04 | PRTA | 525 | Prothena Set For Breakout With Upcoming… | 2025-07-20 | 2025-09-30 | 72 | 6.44 | 24.00 | 273% | 6.29 | 9.85 | 9.76 | 56.6% | 55.17% | 55.17% | Missed |
| 32 | 2025-07-04 | IBIO | 83 | AI Driven IBio Poised For Clinical Brea… | 2025-11-01 | 2026-05-01 | 181 | 0.7410 | 1.50 | 102% | |||||||
| 31 | 2025-07-04 | DRRX | 18 | Durect Set To Transform Hepatitis Treat… | 2025-09-01 | 2025-11-30 | 90 | 0.6667 | 2.50 | 275% | 1.94 | 1.97 | 1.91 | 1.55% | -1.55% | -1.55% | Missed |
| 30 | 2025-07-03 | CYCC | 8 | Critical Clinical Trials Approach For C… | 2025-10-25 | 2025-11-30 | 36 | 3.54 | 18.00 | 408% | 1.95 | 2.30 | 1.51 | 17.95% | -22.56% | -22.56% | Missed |
| 29 | 2025-07-03 | TBPH | 909 | Theravance Biopharma Poised For Growth … | 2025-10-01 | 2026-01-31 | 122 | 11.15 | 15.50 | 39% | 14.42 | 21.03 | 18.94 | 45.84% | 31.35% | 7.49% | Breakout |
| 28 | 2025-07-03 | CLSD | 63 | Clearside Biomedical Poised For Breakou… | 2025-06-01 | 2025-09-30 | 121 | 12.18 | 45.00 | 269% | 11.10 | 13.50 | 3.97 | 21.61% | -64.23% | -64.23% | Missed |
| 27 | 2025-07-03 | TNXP | 211 | Tonix Pharmaceuticals Poised For Breakt… | 2025-08-10 | 2025-08-20 | 10 | 35.48 | 50.00 | 41% | 44.97 | 69.97 | 36.05 | 55.59% | -19.84% | 11.19% | Breakout |
| 26 | 2025-07-03 | SIGA | 469 | SIGA Set For Surge As TPOXX Phase 3 Tri… | 2025-09-25 | 2025-10-10 | 15 | 6.69 | 9.50 | 42% | 8.78 | 9.29 | 8.22 | 5.81% | -6.38% | -6.38% | Missed |
| 25 | 2025-07-03 | VTVT | 435 | VTv Therapeutics Poised For Breakthroug… | 2025-10-01 | 2026-01-10 | 101 | 15.07 | 28.00 | 86% | 24.00 | 44.00 | 35.58 | 83.33% | 48.23% | 16.67% | Breakout |
| 24 | 2025-07-03 | AMRN | 329 | Amarin Poised For Breakout With Key App… | 2025-07-10 | 2025-08-10 | 31 | 16.73 | 18.50 | 11% | 17.32 | 17.49 | 14.99 | 0.98% | -13.45% | -13.45% | Missed |
| 23 | 2025-07-03 | FATE | 245 | Fate Therapeutics Poised For Breakout O… | 2025-11-01 | 2025-12-31 | 60 | 1.12 | 5.50 | 391% | 1.26 | 1.40 | 0.9826 | 11.07% | -22.02% | -22.02% | Missed |
| 22 | 2025-07-03 | ENTA | 407 | Enanta Set For Breakout On Clinical Tri… | 2025-09-25 | 2025-10-10 | 15 | 7.89 | 16.50 | 109% | 7.75 | 15.34 | 11.02 | 97.94% | 42.19% | 42.19% | Missed |
| 21 | 2025-07-03 | NKTR | 2150 | Promising Phase 2b Trials Propel Nektar… | 2025-07-30 | 2025-08-30 | 31 | 24.76 | 35.00 | 41% | 22.07 | 29.92 | 29.86 | 35.57% | 35.3% | 35.3% | Missed |
| 20 | 2025-07-03 | QURE | 3270 | UniQure Set For Breakout Amid Promising… | 2025-07-10 | 2025-10-14 | 96 | 14.42 | 35.00 | 143% | 14.88 | 65.12 | 58.96 | 337.63% | 296.24% | 135.22% | Breakout |
| 19 | 2025-07-03 | XBIT | 71 | XBiotech Poised For Breakout With Upcom… | 2025-07-10 | 2026-03-01 | 234 | 3.18 | 6.50 | 104% | 2.96 | 3.61 | 2.26 | 21.96% | -23.65% | -23.65% | Missed |
| 18 | 2025-07-03 | MGNX | 306 | MacroGenics Poised For Breakthrough Ami… | 2025-09-25 | 2025-10-10 | 15 | 1.46 | 2.50 | 71% | |||||||
| 17 | 2025-07-02 | VTGN | 29 | Promising Outlook For Vistagen With Upc… | 2025-10-01 | 2025-12-31 | 91 | 2.00 | 4.00 | 100% | 3.55 | 5.14 | 0.6619 | 44.79% | -81.35% | 12.68% | Breakout |
| 16 | 2025-07-02 | ABEO | 320 | Abeona Therapeutics Nears Transformativ… | 2025-07-10 | 2025-08-10 | 31 | 5.89 | 10.00 | 70% | 5.85 | 7.12 | 6.26 | 21.71% | 7.01% | 7.01% | Missed |
| 15 | 2025-07-02 | ASMB | 530 | Assembly Biosciences Near Breakout; Key… | 2025-09-25 | 2025-12-15 | 81 | 18.14 | 25.00 | 38% | 25.53 | 39.71 | 34.60 | 55.52% | 35.53% | Early Breakout | |
| 14 | 2025-07-02 | VSTM | 332 | Verastem Poised For Breakout With Immin… | 2025-07-20 | 2025-08-15 | 26 | 4.80 | 6.50 | 35% | 5.10 | 8.76 | 8.22 | 71.67% | 61.18% | 27.45% | Breakout |
| 13 | 2025-07-02 | ACRS | 698 | Aclaris Eyes Breakout On Upcoming Clini… | 2025-11-28 | 2026-01-15 | 48 | 1.44 | 3.00 | 108% | 2.83 | 3.48 | 2.67 | 22.79% | -5.65% | 6.01% | Breakout |
| 12 | 2025-07-02 | AKBA | 982 | Akebia Therapeutics Set For Breakout Am… | 2025-07-15 | 2025-08-15 | 31 | 3.62 | 6.50 | 80% | 3.88 | 4.04 | 3.25 | 4.12% | -16.24% | -16.24% | Missed |
| 11 | 2025-07-02 | HRTX | 81 | Anticipating Heron Therapeutics' Breako… | 2025-11-20 | 2025-12-15 | 25 | 2.20 | 4.50 | 105% | 1.06 | 1.44 | 1.40 | 36.49% | 32.7% | 32.7% | Missed |
| 10 | 2025-07-02 | CDXS | 217 | Codexis Set To Surge On Breakthrough EC… | 2025-10-01 | 2025-10-31 | 30 | 2.77 | 7.50 | 171% | |||||||
| 9 | 2025-07-02 | MCRB | 68 | Seres Therapeutics Set For Breakout On … | 2025-09-25 | 2025-10-10 | 15 | 11.87 | 15.00 | 26% | 18.90 | 22.00 | 19.12 | 16.4% | 1.16% | Early Breakout | |
| 8 | 2025-07-02 | MNOV | 65 | MediciNova Set For Breakout With Key Cl… | 2025-11-25 | 2026-01-10 | 46 | 1.25 | 5.00 | 300% | 1.52 | 1.60 | 1.52 | 5.26% | 0% | 0% | Missed |
| 7 | 2025-07-02 | CAPR | 1530 | Capricor Poised For Breakout With Promi… | 2025-08-01 | 2025-09-30 | 60 | 10.25 | 18.00 | 76% | 7.90 | 9.43 | 7.21 | 19.37% | -8.73% | -8.73% | Missed |
| 6 | 2025-07-02 | SAGE | 581 | Sage Therapeutics Set For Breakout On U… | 2025-07-15 | 2025-08-15 | 31 | 9.20 | 12.50 | 36% | 9.17 | 9.19 | 8.68 | 0.22% | -5.34% | -5.34% | Missed |
| 5 | 2025-07-02 | SGMO | 74 | Sangamo Poised For Breakout With Forthc… | 2025-12-01 | 2026-06-30 | 211 | 0.5269 | 4.50 | 754% | 0.4254 | 0.6000 | 0.0740 | 41.04% | -82.6% | -82.6% | Missed |
| 4 | 2025-07-02 | GALT | 329 | Promising Trial Results Could Propel Ga… | 2025-09-20 | 2025-10-20 | 30 | 2.18 | 6.00 | 175% | 4.92 | 5.35 | 5.09 | 8.74% | 3.46% | 3.46% | Missed |
| 3 | 2025-07-02 | OMER | 627 | Omeros Set For Potential Breakout Ahead… | 2025-09-20 | 2025-10-05 | 15 | 3.20 | 8.00 | 150% | 4.30 | 4.59 | 4.58 | 6.74% | 6.51% | 6.51% | Missed |
| 2 | 2025-07-02 | CRMD | 616 | CorMedix Set For Breakout With DefenCat… | 2025-10-25 | 2026-01-25 | 92 | 11.62 | 18.00 | 55% | 11.05 | 13.02 | 7.27 | 17.83% | -34.21% | -34.21% | Missed |
| 1 | 2025-07-02 | LXRX | 1130 | Lexicon Pharmaceuticals Set For Breakou… | 2025-09-20 | 2025-12-31 | 102 | 0.9010 | 3.00 | 233% |